Applied Therapeutics (NASDAQ:APLT) Shares Down 3%

Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) dropped 3% during trading on Monday . The stock traded as low as $4.47 and last traded at $4.53. Approximately 82,514 shares traded hands during trading, a decline of 95% from the average daily volume of 1,608,875 shares. The stock had previously closed at $4.67.

Analysts Set New Price Targets

APLT has been the topic of several analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $12.00 price target on shares of Applied Therapeutics in a research report on Thursday, April 11th. UBS Group lifted their price target on shares of Applied Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Friday, March 15th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $11.00.

Applied Therapeutics Trading Down 5.6 %

The company’s fifty day moving average is $4.50 and its two-hundred day moving average is $4.50. The stock has a market cap of $497.07 million, a price-to-earnings ratio of -2.36 and a beta of 1.99.

Applied Therapeutics (NASDAQ:APLT) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.09). The business had revenue of $0.19 million for the quarter, compared to analyst estimates of $10.00 million. Analysts predict that Applied Therapeutics, Inc. will post -0.59 EPS for the current year.

Insiders Place Their Bets

In other Applied Therapeutics news, CEO Shoshana Shendelman sold 61,795 shares of the business’s stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $4.32, for a total value of $266,954.40. Following the completion of the transaction, the chief executive officer now owns 3,756,019 shares in the company, valued at $16,226,002.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CEO Shoshana Shendelman sold 61,795 shares of the business’s stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $4.32, for a total transaction of $266,954.40. Following the completion of the transaction, the chief executive officer now owns 3,756,019 shares in the company, valued at $16,226,002.08. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Real Estate Equitie Alexandria sold 150,000 shares of the business’s stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $4.21, for a total transaction of $631,500.00. Following the transaction, the insider now owns 6,005,077 shares of the company’s stock, valued at approximately $25,281,374.17. The disclosure for this sale can be found here. Insiders sold a total of 250,778 shares of company stock worth $1,066,861 over the last 90 days. Corporate insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Applied Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of APLT. AIGH Capital Management LLC lifted its position in Applied Therapeutics by 109.1% in the fourth quarter. AIGH Capital Management LLC now owns 1,659,039 shares of the company’s stock valued at $5,558,000 after acquiring an additional 865,689 shares during the last quarter. Opaleye Management Inc. lifted its position in Applied Therapeutics by 22.3% in the fourth quarter. Opaleye Management Inc. now owns 1,092,500 shares of the company’s stock valued at $3,660,000 after acquiring an additional 199,500 shares during the last quarter. Vestal Point Capital LP purchased a new stake in Applied Therapeutics in the fourth quarter valued at $13,919,000. Worth Venture Partners LLC lifted its position in Applied Therapeutics by 112.9% in the fourth quarter. Worth Venture Partners LLC now owns 412,981 shares of the company’s stock valued at $1,383,000 after acquiring an additional 219,008 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC purchased a new stake in Applied Therapeutics in the third quarter valued at $1,139,000. Institutional investors and hedge funds own 98.31% of the company’s stock.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.